BioXcel Therapeutics (BTAI) Operating Leases (2019 - 2024)
BioXcel Therapeutics (BTAI) posted quarterly Operating Leases of $65000.0 for Q4 2024, down 85.23% year-over-year from $440000.0 in Q1 2024, and down 59.63% quarter-over-quarter from $161000.0 in Q3 2024.
BioXcel Therapeutics (BTAI) Operating Leases (2019 - 2024) Analysis & Trends
BioXcel Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $65000.0 for Q4 2024.
- In Q4 2024, Operating Leases fell 85.23% year-over-year to $65000.0; the TTM figure through Dec 2024 stood at $65000.0 (down 85.23% YoY), while the FY2024 annual figure was $65000.0, down 85.23% from the prior year.
- Operating Leases for Q4 2024 stood at $65000.0, down from $161000.0 in the prior quarter.
- The five-year high for Operating Leases was $1.5 million in Q3 2020, with the low at $65000.0 in Q4 2024.
- The 5-year median for Operating Leases is $887500.0 (2020), against an average of $817650.0.
- The sharpest annual moves came in 2021 and 2024: Operating Leases soared 38.37% in 2021, then slumped 85.23% in 2024.
- BioXcel Therapeutics' Operating Leases stood at $1.4 million in 2020, then dropped by 20.96% to $1.1 million in 2021, then declined by 28.87% to $786000.0 in 2022, then slumped by 44.02% to $440000.0 in 2023, then plunged by 85.23% to $65000.0 in 2024.
- Business Quant data shows BTAI's Operating Leases at $65000.0 in Q4 2024, $161000.0 in Q3 2024, and $256000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.45 Bn | 43.48 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.60 Bn | 39.95 Bn | 2.15 Bn |
| 3 | Zoetis | 32.45 Bn | 30.77 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn |
| 6 | Viatris | 18.99 Bn | 18.10 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.98 Bn | 11.45 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | BioXcel Therapeutics | 24.84 Mn | 24.84 Mn | 160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 65,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Mar 31, 2024 | 350,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Sep 30, 2023 | 529,000.00 |
| Jun 30, 2023 | 617,000.00 |
| Mar 31, 2023 | 703,000.00 |
| Dec 31, 2022 | 786,000.00 |
| Sep 30, 2022 | 868,000.00 |
| Jun 30, 2022 | 949,000.00 |
| Mar 31, 2022 | 1.03 Mn |
| Dec 31, 2021 | 1.11 Mn |
| Sep 30, 2021 | 1.18 Mn |
| Jun 30, 2021 | 1.26 Mn |
| Mar 31, 2021 | 1.33 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.47 Mn |
| Jun 30, 2020 | 907,000.00 |
| Mar 31, 2020 | 961,000.00 |